Oncology
Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab or cetrelimab alone in patients with muscle-invasive bladder cancer: SunRISe-4 primary analysis and biomarker results
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.